Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I seriously do not know what EAPH can do. They need volume! There is plain and simply not nearly enough. I feel like the stock will keep slowly bleeding away unless somehow volume picks up. They have had tremendous news and yet no one seems to care. I cannot explain it besides that no one must trust them. I believe in this company and eventually it will go up big!
All I can say is WOW!!!!! HUGE up day coming Monday! Unreal! IMO .02 close tomorrow.
CEN BIOTECH: THE THIN RED LINE 7 comments
Feb 22, 2015 12:15 PM | about stocks: FITX
courtesy Jerry Al-Mufleh
Brief History of Health Canada vs Federal Courts
The constitutional validity of Health Canada has again come under heavy scrutiny. The recent federal government sponsored MMPR program has made significant improvements since its transition from a MMAR program, but yet faces inherent risks and challenges for many applicants today. Consequently, fair and appropriate regulation has transformed into a bureaucratic corruptive mechanism, causing unnecessary distress for both Health Canada and applicants. A full appreciation of the gravity of the situation requires a brief history in the transition from the MMAR program to the MMPR program for medical marijuana.
In 1999, Health Canada initiated a centralized federal medicinal cannabis program largely due to a court challenge by Jim Wakeford, whom required medicinal cannabis to help alleviate his HIV/AIDS symptoms, but was denied access. The Ontario Superior Court readily recognized Mr. Wakeford's legal right to "access cannabis without fear of arrest, and instructed Health Canada to create a process allowing for legal access to this medicine [cannabis]" (See Wakeford v. the Queen, 1999)
In 2001 the Ontario Court of Appeals struck down Health Canada's Section 56 program as unconstitutional in regards to medicinal marijuana and ordered Health Canada to develop the Marijuana Medical Access Division (MMAD), and implement the Marijuana Medical Access Regulations (MMAR). Almost two years later, Health Canada initiated the MMAR program for medicinal marijuana.
It was a ruling on Jan 9th, 2003 that the Supreme Court ordered Health Canada to create a readily available supply of cannabis for patients under a contracted company called Prairie Plant Systems (NYSE:PPS).
On July 8th, 2003, Health Canada introduced the MMAR program to Canada, and had become the second nation in the world to provide a robust system for access to medical grade marijuana via a centralized government sponsored program.
Yet the MMAR program had many intrinsic problems in regards to its interpretation and limits, and PPS lacked several components to successfully integrate the program into the general public. Furthermore, the degree of rigor involved in controlling production of marijuana and providing access to patients was astonishing, causing many patients in dire need of the medicine to suffer significantly due simply to limited access. In other words, many patients were limited in supply and the unanticipated problems with quality control and management of medical cannabis was proving to be difficult for Praire Plant Systems to handle as one government entity.
On October 7th, 2003, the Ontario Supreme Court upheld the right for patients to have access to safe, legal source of medical cannabis and again found the federal program under the MMAR as unconstitutional for creating "the illusion of access", as stated by Provincial Judge Lederman.
Canadian Press:
"Health Canada is requiring taxpayers and medical cannabis patients to fund inefficient practices, capital upgrades, and equipment for a private contractor [PPS]. Instead of providing affordable medicine to those in need, Health Canada has chosen a policy and program that seemingly creates a windfall for one monopoly supplier to the detriment of patients and taxpayers. While community-based medical cannabis dispensaries provide a cost-effective alternative to Health Canada's centralized monopoly for cultivation and distribution, the end-cost to patients still remains problematic."
In February 2005 Canadian Press reported that according to Health Canada, 127 of the 278 patients ordering PPS cannabis from the government at the time were in arrears, for a total of $168,879 in unpaid medical cannabis bills. Health Canada responded by sending collection agencies after those in arrears for more than 180 days, cutting off at least 19 authorized users from ordering medical cannabis from the nation's only legal supplier, and forcing these critically and chronically ill Canadians to resort to accessing their medicine from illicit sources
In 2005, the Canadian Senate Special Committee on Illegal Drugs and the Ontario Court of Appeals suggested that Health Canada readily cooperate with compassion societies (similar to licensed producers) with the goal of improving access to a safe supply of cannabis for patients.
After significant strides and hurdles, the Government of Canada, ordered Health Canada to provide reasonable access to legal source of marijuana to patients and a drastic change in its MMAR program was implemented. These "compassion societies" existing today, have uniquely been transformed into pharmaceutical grade cannabis facilities under the new Marihuana for Medical Purposes Regulations (MMPR).
For further interest regarding the historical transition of MMAR to MMPR, please visit the published article here.
CEN Biotech
Close examination of the historical context of the MMAR program suggests that Health Canada may indeed require the guidance of the Ontario Court system to address the injustice surrounding CEN Biotech. To this end, the Ontario Court of Canada and the Canadian Senate Special Committee will most likely overturn Health Canada's reluctant demeanor in CEN Biotech's stagnant license delays, and again strike down unjust political drive from some CEN Biotech opponents to help protect honest open trade practices for the future and beyond.
CEN Biotech makes a strong case
Investors have become aware that Health Canada has again been increasingly prejudice against CEN Biotech's license approval. The salient purpose of CEN Biotech's facility is to provide patients with high quality medical grade marijuana in one of the most advanced pharmaceutical facilities constructed to date. The recent trend of corruption from Health Canada and the town of Lakeshore amounts to one of the most unprecedented challenges that MMPR applicants such as CEN Biotech face today. In a recent cross-national poll, many believe that Health Canada has been grossly negligent in their relationship with CEN Biotech, and are plagued by corruption in an array of contradicting statements, news leaks to media outlets, and retroactive change in policies (Lakeshore) aimed specifically to prevent CEN Biotech from obtaining licensure. No other applicant to date has been under such heavy attack and contentious critique that engenders a serious discussion among investors, shareholders, patients, and the private sector.
Investors are rightfully upset, and have taken notice that this corruptive behavior has far-reaching tentacles than just Globe and Mail, and may have tainted even a few Health Canada officials, in a concerted effort to prevent CEN Biotech from obtaining licensure.
CEN Biotech provides well supported documents
On February 20th, official court documents surfaced to investors regarding CEN Biotech's proactive action against Health Canada. For more information regarding this particular event, please visit MMJ.TODAY for a detailed discussion regarding the current status of CEN Biotech's license application.
The ramifications of these documents are paramount to the entire MMPR program. Health Canada has clearly contradicted their proceedings and approvals regarding CEN Biotech's facility. This table aims to focus in part certain documented evidence addressing Health Canada's erratic and seismic shift in opinion.
(click to enlarge)
George Routhier, MMPR CONSULTANT
This begs any competent individual to ponder how would section SS.26, and SS. 38 be an issue subsequent to approval of a ready to build letter? Moreover, at what point did Health Canada show concern regarding the company's zoning issues when inspection was completed successfully? Most importantly, Lakeshore contradicted their own bylaws and retroactively modified their zoning parameters for medical marijuana facilities to specifically steer Health Canada to reject CEN Biotech's application. This is a clear case of a legal non-conforming issue. These questions are substantial to ask any judicial council, and a naive ignorance of the underlying agendas of the laws does not merit approval and is not an pretext for rejection.
Many notable public figures such as George Routhier, a medical marijuana MMPR consultant has noted that CEN Biotech may just rightfully deserves license as they have been lawfully processed from the initial stages of the application to the end. He explains:
What's Next?
CEN Biotech has constantly developed the intuition to communicate across all barriers and obstacles. Health Canada has reluctantly refused to communicate with CEN Biotech as of August 2014, yet were readily available to release private important information to Globe and Mail with no regard to contacting CEN Biotech before media outlets obtained information.
Professionalism, honesty, service, and compassion are lifelong personal satisfactions that become a source of strength for many successful companies. It is these very values that have driven and motivated CEN Biotech to surpass any obstacle and strive to give Canada their undivided concentration and care. It is also these qualities that have attracted such a powerful versatile board of directors and reach global trade agreements with countries around the world.
CEN Biotech is sensitive to the sentiments of the political agenda from various competitors and only wish for a code of conduct that is fair and just use of practice. The true mission of CEN Biotech is to provide service to patients, and inspire others to develop the resilience necessary to withstand the failures and frustrations of adverse circumstances. In short, it is my belief that the Federal Courts of Canada will undoubtedly provide a swift decision that emulates the fair and just practices of the past, while providing much needed guidance to Health Canada in their application process for qualified applicants such as CEN Biotech.
Disclosure: The author is long FITX.
Themes: marijuana, health canada, facility, lakeshore, justice, corruption, bylaws, no zoning issues Stocks: FITX
Great post! Big day ahead Monday. Could test .02 imo. Monday morning last chance to get in!
Everyone is analyzing financials, the letter, etc. This is penny land. It's ridiculous but all of that stuff doesn't matter for the short term. Because of the letter to shareholders, I think it is going to be an up day today. Great stock to day trade. Looking for a big gap up today. I think sometimes you have to throw out all logic in penny land....lol.
I don't believe in this company at all but as a day trader, I think tomorrow will be a very good day. Should jump way up imo
So what does everyone think about tomorrow? I say FITX jumps up tomorrow. I am not saying it deserves to but I think it will from the pr.......keeps them on life support for awhile anyways and keeps the mj alive for now.
I don't know about the overall future of the company but one thing I know. This stock is going to fly now for 2 days imo
FITX RUNNING AGAIN! NEWS OUT!
Wow I am shocked at the news! Maybe I was wrong?
I don't get it. How will they prevail? They are already rejected.....made up a fake person in the company....etc. How will they prevail.....selling energy drinks? Really?
I don't get why people are still buying this stock. I assume most bought in because of the medical marijuana. Now it's dead so why? I still believe in the marijuana stocks like EAPH, VAPE, etc. EAPH the most upside.
EAPH - Big mj play. Way undervalued. See below.
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
2 days 1 hours 4 minutes ago - DJNF
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
HUMBOLDT, CA--(Marketwired - Feb 17, 2015) - Easton Pharmaceuticals Inc (OTC PINK: EAPH) unveils Medicated Markets revenue projections for fiscal year 2015.
In January of 2015, prices have increased for medicinal marijuana to $2185.00 per pound In California (dispensaries in the greater LA region as clarified in past communications) as an average. This is a marked increase from December 2014 prices of $1925.00 per pound. Revenue distribution is expected be stable throughout the year as a growth cycle is used for plants in various stages of development. Yield in prior harvests have consistently yielded 1.5 lbs per plant on average.
Clone to Sale revenue guidance are as follows:
Total plants grown being 10,000 x 1.5lbs yield = 15,000 lbs x $2185.00 approximate sales price
Revenue based on these targets stand at $32,775,000
In other related news, Easton Pharmaceuticals have initiated discussions with a Canadian MMAR Licensed grower to obtain legal active cannabinoids for its OTC topical formulations.
Questions relating to Medicated Markets Operations should be sent to info@medicatedmarkets.com where quick responses to any queries can be expected.
Mr. M Farrugia asked if any portion of future marijuana product has been pre-sold to lock in prices and when an expected 8K filing related to this transaction is to be made public. Our current dispensaries are allowed to purchase up to 60 days prior to delivery on any specific strains to maintain availability at their locations. An 8K filing is to be soon be disclosed by Easton.
I talk to them all the time by email. They almost always answer all of my questions. I am very comfortable with my investment.
Anyone have any ideas why we are down? Seriously....wt-! Makes no sense.
Seriously people. 13 million revenue for a mj penny company. Unheard of! This is only the beginning. Wait until we are growing in Canada also. Then add in vapor sales. We could see the day where Easton has 100 million in revenue. Not that long from now either. Not a dream.
EAPH NEWS OUT!! 32 MILLION IN EXPECTED REVENUE!!!!!
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
22 minutes ago - DJNF
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
HUMBOLDT, CA--(Marketwired - Feb 17, 2015) - Easton Pharmaceuticals Inc (OTC PINK: EAPH) unveils Medicated Markets revenue projections for fiscal year 2015.
In January of 2015, prices have increased for medicinal marijuana to $2185.00 per pound In California (dispensaries in the greater LA region as clarified in past communications) as an average. This is a marked increase from December 2014 prices of $1925.00 per pound. Revenue distribution is expected be stable throughout the year as a growth cycle is used for plants in various stages of development. Yield in prior harvests have consistently yielded 1.5 lbs per plant on average.
Clone to Sale revenue guidance are as follows:
Total plants grown being 10,000 x 1.5lbs yield = 15,000 lbs x $2185.00 approximate sales price
Revenue based on these targets stand at $32,775,000
In other related news, Easton Pharmaceuticals have initiated discussions with a Canadian MMAR Licensed grower to obtain legal active cannabinoids for its OTC topical formulations.
Questions relating to Medicated Markets Operations should be sent to info@medicatedmarkets.com where quick responses to any queries can be expected.
Mr. M Farrugia asked if any portion of future marijuana product has been pre-sold to lock in prices and when an expected 8K filing related to this transaction is to be made public. Our current dispensaries are allowed to purchase up to 60 days prior to delivery on any specific strains to maintain availability at their locations. An 8K filing is to be soon be disclosed by Easton.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2015 09:00 ET (14:00 GMT)
Good point. I do not know that. I initially assumed the year but maybe you are on to something.
EAPH NEWS!!! HUGE!!!! Projected revenues of 32 million. Yes million
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
8 minutes ago - DJNF
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
HUMBOLDT, CA--(Marketwired - Feb 17, 2015) - Easton Pharmaceuticals Inc (OTC PINK: EAPH) unveils Medicated Markets revenue projections for fiscal year 2015.
In January of 2015, prices have increased for medicinal marijuana to $2185.00 per pound In California (dispensaries in the greater LA region as clarified in past communications) as an average. This is a marked increase from December 2014 prices of $1925.00 per pound. Revenue distribution is expected be stable throughout the year as a growth cycle is used for plants in various stages of development. Yield in prior harvests have consistently yielded 1.5 lbs per plant on average.
Clone to Sale revenue guidance are as follows:
Total plants grown being 10,000 x 1.5lbs yield = 15,000 lbs x $2185.00 approximate sales price
Revenue based on these targets stand at $32,775,000
In other related news, Easton Pharmaceuticals have initiated discussions with a Canadian MMAR Licensed grower to obtain legal active cannabinoids for its OTC topical formulations.
Questions relating to Medicated Markets Operations should be sent to info@medicatedmarkets.com where quick responses to any queries can be expected.
Mr. M Farrugia asked if any portion of future marijuana product has been pre-sold to lock in prices and when an expected 8K filing related to this transaction is to be made public. Our current dispensaries are allowed to purchase up to 60 days prior to delivery on any specific strains to maintain availability at their locations. An 8K filing is to be soon be disclosed by Easton.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2015 09:00 ET (14:00 GMT)
HUGE EAPH NEWS......EAPH NEWS!!!!! Projected revenue of $32 MILLION
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
8 minutes ago - DJNF
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
HUMBOLDT, CA--(Marketwired - Feb 17, 2015) - Easton Pharmaceuticals Inc (OTC PINK: EAPH) unveils Medicated Markets revenue projections for fiscal year 2015.
In January of 2015, prices have increased for medicinal marijuana to $2185.00 per pound In California (dispensaries in the greater LA region as clarified in past communications) as an average. This is a marked increase from December 2014 prices of $1925.00 per pound. Revenue distribution is expected be stable throughout the year as a growth cycle is used for plants in various stages of development. Yield in prior harvests have consistently yielded 1.5 lbs per plant on average.
Clone to Sale revenue guidance are as follows:
Total plants grown being 10,000 x 1.5lbs yield = 15,000 lbs x $2185.00 approximate sales price
Revenue based on these targets stand at $32,775,000
In other related news, Easton Pharmaceuticals have initiated discussions with a Canadian MMAR Licensed grower to obtain legal active cannabinoids for its OTC topical formulations.
Questions relating to Medicated Markets Operations should be sent to info@medicatedmarkets.com where quick responses to any queries can be expected.
Mr. M Farrugia asked if any portion of future marijuana product has been pre-sold to lock in prices and when an expected 8K filing related to this transaction is to be made public. Our current dispensaries are allowed to purchase up to 60 days prior to delivery on any specific strains to maintain availability at their locations. An 8K filing is to be soon be disclosed by Easton.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2015 09:00 ET (14:00 GMT)
NEWS!!!!!! $12,800,000 REVENUE FOR EAPH.....Yes....almost 13 million!!!!!!!!!!!!!
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
8 minutes ago - DJNF
Easton Pharmaceuticals Unveils Medicated Markets Revenue Projections for Fiscal 2015
HUMBOLDT, CA--(Marketwired - Feb 17, 2015) - Easton Pharmaceuticals Inc (OTC PINK: EAPH) unveils Medicated Markets revenue projections for fiscal year 2015.
In January of 2015, prices have increased for medicinal marijuana to $2185.00 per pound In California (dispensaries in the greater LA region as clarified in past communications) as an average. This is a marked increase from December 2014 prices of $1925.00 per pound. Revenue distribution is expected be stable throughout the year as a growth cycle is used for plants in various stages of development. Yield in prior harvests have consistently yielded 1.5 lbs per plant on average.
Clone to Sale revenue guidance are as follows:
Total plants grown being 10,000 x 1.5lbs yield = 15,000 lbs x $2185.00 approximate sales price
Revenue based on these targets stand at $32,775,000
In other related news, Easton Pharmaceuticals have initiated discussions with a Canadian MMAR Licensed grower to obtain legal active cannabinoids for its OTC topical formulations.
Questions relating to Medicated Markets Operations should be sent to info@medicatedmarkets.com where quick responses to any queries can be expected.
Mr. M Farrugia asked if any portion of future marijuana product has been pre-sold to lock in prices and when an expected 8K filing related to this transaction is to be made public. Our current dispensaries are allowed to purchase up to 60 days prior to delivery on any specific strains to maintain availability at their locations. An 8K filing is to be soon be disclosed by Easton.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their groZONE anti-microbial airflow system needed for growing pesticide free medicine, and have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
For More Information Visit:
http://www.eastonpharmaceuticalsinc.com
http://ecigmarkets.com/
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact:
Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: info@eastonpharmaceuticalsinc.com
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2015 09:00 ET (14:00 GMT)
40% OF 32,000,000 = $12,800,000 REVENUE FOR EAPH!!!!!!!!!!!!!!!
The only big money here is the 1000's of day traders that jumped on board last week and this week they will be jumping back off again imo. IMO, if you are holding your shares, you won't have any money left. GLTY
CEN Biotech’s attempt to open the world’s largest medical marijuana facility in Canada is being blocked by the federal government.
Amid serious questions about the company’s conduct, including allegations of misrepresentation and false claims by the CEO, Health Canada informed CEN Biotech in a letter late Friday that the government intends to refuse its application for a licence.
MORE RELATED TO THIS STORY
Health Canada puts medical marijuana firm under further RCMP review
GLOBE EDITORIAL Has Health Canada oversight of medical marijuana gone to pot?
Under fire, marijuana firm invented employee to dispute claims
The gate at CEN Biotech’s main facility in Lakeshore, Ont.
MULTIMEDIA
Marijuana firm’s reply to controversy sparks more doubt on claims
A no trespassing sign hangs on the outer fence of CEN Biotech's main facility in Lakeshore, Ontario, Saturday, December 6, 2014.
MULTIMEDIA
Globe Investigation: How much does Ottawa know about the medical marijuana companies it's licensing?
STOCKS
Video: In a booming industry, medical marijuana company makes problematic claims
“Based on a thorough assessment in line with the extensive requirements built into the Medical Marijuana Program, Health Canada has advised CEN Biotech of its intent to reject its application,” Health Canada spokesman Stéphane Shank said in a statement to The Globe and Mail.
The move comes after a Globe and Mail investigation detailed a series of misrepresentations by the company to investors and regulators. These included claims to investors that the company had been licensed, or was on the verge of being licensed, by Health Canada, when it was not. Those claims helped significantly drive up the stock price of CEN’s parent company, Creative Edge Nutrition Inc. Meanwhile, the CEO was quietly selling large numbers of shares at a substantial profit.
Other problems have come to light in recent weeks, including revelations that the company invented an employee named Isak Weber to act as a spokesman to dispute the findings of The Globe’s investigation. After it was revealed that Mr. Weber did not exist, the company’s CEO Bill Chaaban said the name was a “nom de plume” for an employee named Roger Glasel.
Mr. Chaaban did not say why Mr. Glasel could not use his real name in a press release issued to the financial markets, and compared the matter to companies using mascots, such as Ronald McDonald and Mr. Clean.
The company then drew more attention in Ottawa when it emerged that CEN executives were claiming Mr. Glasel had ties to Health Minister Rona Ambrose. That forced Ms. Ambrose’s office to take the unusual step of issuing a statement that said she did not know Mr. Glasel and “is disturbed by the allegation he is using her name without her permission or knowledge.”
As well, the emergence of documents filed with regulators that show multiple different signatures attributed to Mr. Chaaban raised further questions about the company. In response, Mr. Chaaban said it did not matter how he signed his name and that he could sign with his feet if he wanted. But amid these mounting concerns, Health Canada decided on Jan. 30 to have the RCMP review the company’s licence application.
“Health Canada has in place a rigorous screening process,” Mr. Shank’s statement said. “This helps ensure that the operations of Licenced Producers do not pose a safety or security risk to Canadians and to the local communities in which they are set up.”
CEN Biotech will be denied a licence to grow medicinal marijuana in Lakeshore, Ont., according to a statement by Health Canada.
The company applied to grow about 590,000 kilograms (1.3 million pounds) of marijuana a year in a production plant off Manning Road.
"Health Canada has in place a rigorous screening process for applicants seeking a license to produce under the Marijuana for Medical Purposes Regulations (MMPR)," a statement from Health Canada reads. "This helps ensure that the operations of Licensed Producers do not pose a safety or security risk to Canadians and to the local communities in which they are set up.
"Based on a thorough assessment in line with the extensive requirements built into the Medical Marijuana Program, Health Canada has advised CEN Biotech of its intent to reject its application."
CEN Biotech has 20 days to provide a reason to Health Canada to change its mind before the decision is final.
Application sent to RCMP
In January, Health Canada confirmed the company's application was sent to the RCMP for further review after a series of Globe and Mail articles called into question the company's investment practices.
"The allegations against this company are deeply concerning. The application is with the RCMP to complete the security assessment, and it won't be going anywhere until all issues are addressed," Health Canada Michael Bolkenius said last month in a statement to CBC News.
The president of CEN Biotech, Bill Chaaban, said the Globe and Mail stories contained unsupported complaints against him and his company and said the paper "misrepresents ordinary business practices as questionable."
Zoning issues
In January 2014, Cen Biotech announced it was investing $12 million in a facility in Lakeshore to grow medicinal marijuana.
The announcement received much fanfare from the town and the Windsor Essex Economic Development Corporation.
The company built its Lakeshore facility on Manning Road on a piece of land zoned for agricultural use.
But the company ran into opposition from the public. Police were called in during a public meeting when a debate over the location of the facility became heated.
The town passed a zoning bylaw amendment last year restricting medical marijuana facilities to land zoned for industrial use, a decision CEN Biotech is appealing.
Health Canada told CBC that it has rejected 224 applications to grow medical marijuana and returned more than 600 to applicants due to being incomplete.
About 25 facilities have been approved.
They are not looking great imo. Lied to Health Canada and their license is rejected. Don't lie to people. Post the facts. I know it sucks being stuck but move on imo.
IMO, the only thing that will be happening at the FITX site is hiring a realtor to sell the property.
Let me first say I am not long or short FITX. Have no position either way. I day traded it last week and that's about it. If you are holding shares I feel sorry for you. Been in this same position before when I was a HUGE shareholder in FSP- when it got haulted by the SEC. My opinion only but FITX should go down huge. I don't even think there is a bottom. I personally wouldn't even day trade this now. How can there be a bottom when their license was rejected? What's left? Alot of people here stuck with shares want other people to think everything is fine and they will be the first to dump shares imo. I am not happy about any of this. I invest in the mj sector and this is another black eye for the sector. Makes people lose confidence in all the mj companies unfortunately. I am invested now HUGE in EAP- so I am not happy overall for the sector. Again, if you are a shareholder, sorry again for you.
Don't forget too, when the Canadian gov't reviews EAPH license, we are now partnered with a company that already grows and sells medical marijuana. Instantly makes us legit and imo gives us a 100% chance of getting the license.
Google search Cen Biotech.......articles are there.
Not that I know if it will happen or not but wouldn't surprise me to see class action lawsuits follow. Look at all of the ones on MDBX.
Tuesday will be interesting:
Ottawa rejects marijuana firm CEN Biotech’s licence application
GRANT ROBERTSON
The Globe and Mail
Published Saturday, Feb. 14 2015, 6:00 AM EST
Last updated Saturday, Feb. 14 2015, 6:00 AM EST
Comments closed
CEN Biotech’s attempt to open the world’s largest medical marijuana facility in Canada is being blocked by the federal government.
Amid serious questions about the company’s conduct, including allegations of misrepresentation and false claims by the CEO, Health Canada informed CEN Biotech in a letter late Friday that the government intends to refuse its application for a licence.
“Based on a thorough assessment in line with the extensive requirements built into the Medical Marijuana Program, Health Canada has advised CEN Biotech of its intent to reject its application,” Health Canada spokesman Stéphane Shank said in a statement to The Globe and Mail.
The move comes after a Globe and Mail investigation detailed a series of misrepresentations by the company to investors and regulators. These included claims to investors that the company had been licensed, or was on the verge of being licensed, by Health Canada, when it was not. Those claims helped significantly drive up the stock price of CEN’s parent company, Creative Edge Nutrition Inc. Meanwhile, the CEO was quietly selling large numbers of shares at a substantial profit.
Other problems have come to light in recent weeks, including revelations that the company invented an employee named Isak Weber to act as a spokesman to dispute the findings of The Globe’s investigation. After it was revealed that Mr. Weber did not exist, the company’s CEO Bill Chaaban said the name was a “nom de plume” for an employee named Roger Glasel.
Mr. Chaaban did not say why Mr. Glasel could not use his real name in a press release issued to the financial markets, and compared the matter to companies using mascots, such as Ronald McDonald and Mr. Clean.
The company then drew more attention in Ottawa when it emerged that CEN executives were claiming Mr. Glasel had ties to Health Minister Rona Ambrose. That forced Ms. Ambrose’s office to take the unusual step of issuing a statement that said she did not know Mr. Glasel and “is disturbed by the allegation he is using her name without her permission or knowledge.”
As well, the emergence of documents filed with regulators that show multiple different signatures attributed to Mr. Chaaban raised further questions about the company. In response, Mr. Chaaban said it did not matter how he signed his name and that he could sign with his feet if he wanted. But amid these mounting concerns, Health Canada decided on Jan. 30 to have the RCMP review the company’s licence application.
“Health Canada has in place a rigorous screening process,” Mr. Shank’s statement said. “This helps ensure that the operations of Licenced Producers do not pose a safety or security risk to Canadians and to the local communities in which they are set up.”
CEN Biotech has 20 days to respond to Health Canada’s rejection letter. After that time, the rejection becomes final “unless the company successfully provides a response that causes Health Canada to change its intent,” Mr. Shank said.
Mr. Chaaban said in an e-mail on Friday night he was not aware of any communication from Health Canada. However, Mr. Shank said the company “was informed in writing” on Friday.
Given the issues surrounding CEN Biotech in recent months, the rejection letter appears to send a message to the nascent industry that Health Canada will not licence applicants that do not conduct themselves in a professional manner. The privatized medical marijuana sector was opened April 1, and is being set up under orders from the Supreme Court of Canada.
CEN Biotech applied to grow 600,000 kilograms of medical marijuana, making it the largest applicant under the federal program. So far, the government has licensed 15 companies. More than 1,200 have applied, and more than 500 have been rejected.
“The screening process has been designed with stringent criteria. It will continue to be scrupulously applied to all applicants
http://www.theglobeandmail.com/report-on-business/ottawa-rejects-marijuana-firm-cen-biotechs-licence-application/article23002460/
They said today which actually made no sense to me. I emailed them and told them it made no sense. I hope they switch it to tomorrow morning. More people would see the news then.
I predict .025 close! Then up again Tuesday another 20%+
EAPH - Should be the last time to buy in before the huge run up on Tuesday. No brainer. Per last pr: "Revenue estimates for Medicated Markets facilities fiscal 2015 should be ready for presentation and disclosure on Monday February 16th; with details including exact strains planted this season, and harvest time lines. Questions related to current business posted to info@medicatedmarkets.com will also be answered. All questions need to be submitted by end of day Tuesday February 10th 2015 to be considered."
EAPH - Last chance to buy in today imo with huge pending news Monday.
Per last pr: "Revenue estimates for Medicated Markets facilities fiscal 2015 should be ready for presentation and disclosure on Monday February 16th; with details including exact strains planted this season, and harvest time lines. Questions related to current business posted to info@medicatedmarkets.com will also be answered. All questions need to be submitted by end of day Tuesday February 10th 2015 to be considered."
Someone explain this to me. FIT- has a market cap of 55 mil. and we have a market cap of 15 to 19 mil. What am I missing? IMO, we should be at .07 to .09 right now today.
Basically we gave them around $4,500,000 in company shares. No different than if we took out a loan and gave them $4,500,000 in cash. If Easton makes $450,00 a year or more on the deal then it was worth it. I guess it all comes down to the revenue projections. It will come down to present expected revenue projections and what they expect the revenues to be after expansion as well.
Basically we gave them around $4,500,000 in company shares. No different than if we took out a loan and gave them $4,500,000 in cash. If Easton makes $450,00 a year or more on the deal then it was worth it. I guess it all comes down to the revenue projections. It will come down to present expected revenue projections and what they expect the revenues to be after expansion as well.
Pay attention to this post if you want to make money:
EAPH - Strong buy in my opinion. Here's why:
1. Company announced they will be issuing revenue estimates this Monday. Revenue estimates are expected to be very good which will send the stock way up Tuesday morning.
2. Currently at 0.023. Off of a 2 week high of .03
+. Easy bounce to over .03 in my opinion this Tuesday. 30% gainer easy in my opinion.
EAPH - Strong buy in my opinion. Here's why:
1. Company announced they will be issuing revenue estimates this Monday. Revenue estimates are expected to be very good which will send the stock way up Tuesday morning.
2. Currently at 0.023. Off of a 2 week high of .03
+. Easy bounce to over .03 in my opinion this Tuesday. 30% gainer easy in my opinion.
No need to tell me to hang in there. I am long and strong. I have no plans of selling one single share until it is way above .10. Even then I won't sell many. Just venting. This stock is a diamond and people haven't realized that yet.